Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

(2016) A. M. Menzies et al.   ANNALS OF ONCOLOGY

Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial:

(2016) F. Stephen Hodi et al.   CANCER RESEARCH

Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges

(2016) Francesca Tartari et al.   CANCER TREATMENT REVIEWS

Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review

(2016) M.N Joshi et al.   CLINICAL ENDOCRINOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events

(2016) Elisa González-Rodríguez et al.   ONCOLOGIST

Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes

(2016) Yuka Miyoshi et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy

(2016) Masahide Okamoto et al.   Journal of Diabetes Investigation

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

(2015) Anne Bertrand et al.   BMC Medicine

Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report

(2015) Juan Martin-Liberal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Low programmed cell death-1 (PD-1) expression in peripheral CD4+T cells in Japanese patients with autoimmune type 1 diabetes

(2015) R. Fujisawa et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes

(2015) Mahnaz Mellati et al.   DIABETES CARE

Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes

(2015) Caroline Gaudy et al.   DIABETES CARE

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Mitigating the toxic effects of anticancer immunotherapy

(2014) Tara C. Gangadhar et al.   Nature Reviews Clinical Oncology

Blockade of the Programmed Death-1 (PD1) Pathway Undermines Potent Genetic Protection from Type 1 Diabetes

(2014) Nora M. Kochupurakkal et al.   PLoS One

Genetics of Type 1 Diabetes

(2013) J. A. Noble et al.   Cold Spring Harbor Perspectives in Medicine

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012)

(2012) Akihisa Imagawa et al.   Journal of Diabetes Investigation